ECONOR 0,5% PREMEZCLA MEDICAMENTOSA PARA PIENSO PARA CERDOS

国家: 西班牙

语言: 西班牙文

来源: AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

现在购买

资料单张 资料单张 (PIL)
20-05-2024
产品特点 产品特点 (SPC)
20-05-2024

有效成分:

VALNEMULINA CLORHIDRATO

可用日期:

Novartis Animal Health Gmbh

ATC代码:

QJ01XQ02

INN(国际名称):

VALNEMULINA HYDROCHLORIDE

药物剂型:

PREMEZCLA MEDICAMENTOSA

组成:

Excipientes: HIPROMELOSA, TALCO, SILICE COLOIDAL ANHIDRA, MIRISTATO DE ISOPROPILO, LACTOSA

给药途径:

ADMINISTRACIÓN EN EL ALIMENTO

处方类型:

Sujeto a prescripción veterinaria Bajo control ó supervisión del veterinario

治疗组:

Porcino

治疗领域:

Valnemulina

產品總結:

ECONOR 0,5% PREMEZCLA MEDICAMENTOSA PARA PIENSO PARA CERDOS Bolsa de 25 kg Anulado No comercializado

授权状态:

Anulado

授权日期:

2015-01-02

资料单张

                                [European Medicines Agency logo] European Medicines Agency - Science,
medicines, health [/]
    
Search for medicines ADVANCED DOCUMENT SEARCH
[/ema/index.jsp%3Fcurl=pages/document_library/landing/document_library_search.jsp]
MAIN NAVIGATION	*
Home [/ema/index.jsp%3Fcurl=pages/home/Home_Page.jsp&mid=]	*
Find medicine
[/ema/index.jsp%3Fcurl=pages/includes/medicines/medicines_landing_page.jsp&mid=]	*
Human regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=]	*
Veterinary regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/veterinary_medicines_regulatory.jsp&mid=]	*
Committees
[/ema/index.jsp%3Fcurl=pages/about_us/general/general_content_000217.jsp&mid=]	*
News & events
[/ema/index.jsp%3Fcurl=pages/news_and_events/landing/news_and_events.jsp&mid=]	*
Partners & networks
[/ema/index.jsp%3Fcurl=pages/partners_and_networks/general/general_content_000212.jsp&mid=]	*
About us
[/ema/index.jsp%3Fcurl=pages/about_us/document_listing/document_listing_000426.jsp&mid=]	*
HUMAN MEDICINES
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124]	*
EUROPEAN PUBLIC ASSESSMENT REPORTS
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125]	*
EPARS: BACKGROUND AND CONTEXT
[/../index.jsp%3Fcurl=pages/medicines/general/general_content_000433.jsp&mid=WC0b01ac058067fa25]	*
PATIENT SAFETY
[/../index.jsp%3Fcurl=pages/medicines/landing/pha_listing.jsp&mid=WC0b01ac058001d126]	*
PENDING EC DECISIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/smop_search.jsp&mid=WC0b01ac058001d127]	*
WITHDRAWN APPLICATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/wapp_search.jsp&mid=WC0b01ac058001d128]	*
PAEDIATRICS
[/../index.jsp%3Fcurl=pages/medicines/landing/pip_search.jsp&mid=WC0b01ac058001d129]	*
RARE DISEASE DESIGNATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b]	*
MEDICINES UNDER EVALUATION
[/../index.jsp%3Fcurl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac0580508
                                
                                阅读完整的文件
                                
                            

产品特点

                                [European Medicines Agency logo] European Medicines Agency - Science,
medicines, health [/]
    
Search for medicines ADVANCED DOCUMENT SEARCH
[/ema/index.jsp%3Fcurl=pages/document_library/landing/document_library_search.jsp]
MAIN NAVIGATION	*
Home [/ema/index.jsp%3Fcurl=pages/home/Home_Page.jsp&mid=]	*
Find medicine
[/ema/index.jsp%3Fcurl=pages/includes/medicines/medicines_landing_page.jsp&mid=]	*
Human regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=]	*
Veterinary regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/veterinary_medicines_regulatory.jsp&mid=]	*
Committees
[/ema/index.jsp%3Fcurl=pages/about_us/general/general_content_000217.jsp&mid=]	*
News & events
[/ema/index.jsp%3Fcurl=pages/news_and_events/landing/news_and_events.jsp&mid=]	*
Partners & networks
[/ema/index.jsp%3Fcurl=pages/partners_and_networks/general/general_content_000212.jsp&mid=]	*
About us
[/ema/index.jsp%3Fcurl=pages/about_us/document_listing/document_listing_000426.jsp&mid=]	*
HUMAN MEDICINES
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124]	*
EUROPEAN PUBLIC ASSESSMENT REPORTS
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125]	*
EPARS: BACKGROUND AND CONTEXT
[/../index.jsp%3Fcurl=pages/medicines/general/general_content_000433.jsp&mid=WC0b01ac058067fa25]	*
PATIENT SAFETY
[/../index.jsp%3Fcurl=pages/medicines/landing/pha_listing.jsp&mid=WC0b01ac058001d126]	*
PENDING EC DECISIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/smop_search.jsp&mid=WC0b01ac058001d127]	*
WITHDRAWN APPLICATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/wapp_search.jsp&mid=WC0b01ac058001d128]	*
PAEDIATRICS
[/../index.jsp%3Fcurl=pages/medicines/landing/pip_search.jsp&mid=WC0b01ac058001d129]	*
RARE DISEASE DESIGNATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b]	*
MEDICINES UNDER EVALUATION
[/../index.jsp%3Fcurl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac0580508
                                
                                阅读完整的文件